<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01844947</url>
  </required_header>
  <id_info>
    <org_study_id>NUCOG III</org_study_id>
    <secondary_id>2011-004289-14</secondary_id>
    <nct_id>NCT01844947</nct_id>
  </id_info>
  <brief_title>Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract</brief_title>
  <acronym>VINSOR</acronym>
  <official_title>An Exploratory Phase I Study With Sorafenib in Addition to Vinflunine in Progressive Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr Anders Ullén</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pierre Fabre Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nordic Urothelial Cancer Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to analyse the tolerability (side effects and safety) with standard treatment&#xD;
      (Javlor®) with the addition of a second anti-tumour drug: sorafenib (Nexavar®). This is the&#xD;
      first time this treatment combination is studied in humans. Samples of blood, urine and&#xD;
      tumour tissues will be analysed for molecular biomarkers. These biomarkers may potentially&#xD;
      help us in the future in predicting whether a patient will benefit or not from the cancer&#xD;
      treatment. The study also aims to investigate if a newer imaging method, called PET-CT&#xD;
      (positron emission tomography-computed tomography), at an earlier stage (than a normal CT&#xD;
      scan) can identify patients who will benefit from the given treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives&#xD;
&#xD;
        -  To explore the safety of sorafenib in combination with vinflunine in patients with&#xD;
           transitional cell carcinoma of the urothelial tract and to define a recommended phase II&#xD;
           dose for this treatment combination&#xD;
&#xD;
        -  To correlate early tracer 18F-FDG-PET/CT functional imaging readouts with standard&#xD;
           RECIST (version 1.1) evaluations with the intention to explore new endpoints for&#xD;
           targeted therapy&#xD;
&#xD;
        -  To find predictive tumour tissue biomarkers for sorafenib/vinflunine treatment&#xD;
&#xD;
        -  To evaluate serum and urine markers of apoptosis as potential markers of&#xD;
           sorafenib/vinflunine treatment&#xD;
&#xD;
      Rationale/Goal&#xD;
&#xD;
      To evaluate the tolerability and activity of sorafenib combined with vinflunine in patients&#xD;
      with advanced or metastatic urothelial cancer.&#xD;
&#xD;
      Tumour biopsies will be collected before and after one cycle of therapy. The translational&#xD;
      part of this study aims to explore the predictive value of a number of biomarkers related to&#xD;
      the targeted properties of sorafenib and presumptive markers for vinflunine treatment.&#xD;
&#xD;
      In addition, the predictive value of an early functional imaging tracer 18F-FDG-PET/CT will&#xD;
      be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2012</start_date>
  <completion_date type="Actual">June 5, 2018</completion_date>
  <primary_completion_date type="Actual">October 18, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>6 weeks</time_frame>
    <description>Primary endpoint:&#xD;
Define the recommended phase II dose (RPTD) by the number of dose limiting toxicity events (recorded during treatment cycle 1 and 2)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <condition>Bladder Cancer</condition>
  <condition>Renal Pelvis Cancer</condition>
  <condition>Ureter Cancer</condition>
  <condition>Urethra Cancer</condition>
  <arm_group>
    <arm_group_label>vinflunine + sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinflunine</intervention_name>
    <description>Vinflunine (Javlor®, Pierre Fabre Pharma): 320 mg/m2 I.V., day 1, repeated every 21 days for patients with PS 0, adequate renal (creatinine clearance &gt;60 ml/min) and hepatic function (as described in the inclusion criteria). PLEASE NOTE THAT THE 320 mg/m2 ARM IS CLOSED FOR RECRUITMENT.&#xD;
For patients with PS 1, or age 75 to 80 years, or exposed to radiation of the lower pelvis region, or with impaired renal function (creatinine clearance 40-60 ml/min) but adequate hepatic function (as described in the inclusion criteria), the dose of vinflunine is 280 mg/m2 I.V. day 1, repeated every 21 days.</description>
    <arm_group_label>vinflunine + sorafenib</arm_group_label>
    <other_name>Javlor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Sorafenib (Nexavar®, Bayer HealthCare) daily dosage from day 2 through day 21 (repeated every 21 days):&#xD;
Step 1: 400 mg P.O. (i.e. one (1) tablet 200 mg morning and evening, 1+0+1) Step 2: 600 P.O. (i.e. one (1) tablet 200 mg morning and two tablets evening, 1+0+2) Step 3: 800 mg P.O. (i.e. two (2) tablets 200 mg morning and evening, 2+0+2) Doses of sorafenib higher than 400 mg P.O. b.i.d. are not allowed.</description>
    <arm_group_label>vinflunine + sorafenib</arm_group_label>
    <other_name>Nexavar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  signed informed consent;&#xD;
&#xD;
          -  histologically confirmed transitional cell (pure or mixed histology including&#xD;
             transitional cell carcinoma are allowed) carcinoma of the urothelial tract;&#xD;
&#xD;
          -  patients who have received neoadjuvant or adjuvant platinum-containing chemotherapy&#xD;
             and who are diagnosed with locoregional recurrent or metastatic disease prior to or at&#xD;
             the 6-months&quot; visit , are eligible or&#xD;
&#xD;
          -  patients who have received palliative platinum-containing chemotherapy and who are&#xD;
             diagnosed with progression prior to or at the 6-months&quot; visit, are eligible or&#xD;
&#xD;
          -  patients who have contraindication to platinum-containing chemotherapy;&#xD;
&#xD;
          -  previous systemic chemotherapy must have been stopped 14 days before the inclusion&#xD;
             with recovery (G1 or less) from any treatment related toxicity;&#xD;
&#xD;
          -  measurable and/or non-measurable disease using RECIST and defined as: Measurable&#xD;
             disease: lesions that can be measured in at least one dimension and which have not&#xD;
             been previously irradiated. Longest diameter 20 mm with conventional techniques or 10&#xD;
             mm with spiral CT scan or MRI. Non-measurable disease: lesions which have not been&#xD;
             previously irradiated, or longest diameter &lt;20 mm with conventional techniques or &lt;10&#xD;
             mm with spiral CT scan or MRI, or truly non measurable lesions including bone lesions,&#xD;
             ascites, pleural/pericardial effusion, and lymphangitis cutis/pulmonitis;&#xD;
&#xD;
          -  age 18 up to 80 years;&#xD;
&#xD;
          -  ECOG / WHO Performance Status (PS) ≤1;&#xD;
&#xD;
          -  haematological function: haemoglobin ≥100 g/L absolute neutrophil count 1.0 x LL&#xD;
             (lower limit of normal value) platelets 100 x 109/L;&#xD;
&#xD;
          -  hepatic function: bilirubin &lt;1.5 x ULN*, transaminases &lt;2.5 x ULN*&#xD;
&#xD;
             *ULN = upper limit of normal value&#xD;
&#xD;
          -  renal function: creatinine clearance 40 ml/min (measured by either iohexol clearance&#xD;
             or Cr-EDTA technique);&#xD;
&#xD;
          -  Clinically normal cardiac function based on ejection fraction (LVEF assessed by MUGA&#xD;
             or ECHO, LVEF ≥50%);&#xD;
&#xD;
          -  able to swallow and retain oral medication;&#xD;
&#xD;
          -  previous treatment related toxicity must be grade ≤1 at time of inclusion and no&#xD;
             presence of asthenia, hand-foot skin reaction or rash grade &gt;1 (NCI CTCAE v4.0) at&#xD;
             enrolment;&#xD;
&#xD;
          -  no known or suspected allergy to the investigational agent or any agents given in&#xD;
             association with this trial;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  non-transitional cell carcinoma of the urothelial tract (e.g. pure adenocarcinoma or&#xD;
             squamous cell carcinoma);&#xD;
&#xD;
          -  prior treatment with vinflunine;&#xD;
&#xD;
          -  diagnosed brain metastases or leptomeningeal involvement. Brain CT-scans or MRI are&#xD;
             not required unless there is clinical suspicion of central nervous system involvement.&#xD;
&#xD;
          -  peripheral neuropathy G3 (NCI CTCAE v4.0);&#xD;
&#xD;
          -  history of serious or concurrent illness or uncontrolled medical disorder; any medical&#xD;
             condition that might be aggravated by treatment or which could not be controlled:&#xD;
             active infection requiring antibiotics within 2 weeks before the study inclusion,&#xD;
             unstable diabetes mellitus, uncontrolled hypercalcaemia &gt;2.9 mmol/L (or &gt;G2 NCI CTCAE&#xD;
             v4.0), concurrent congestive heart failure NYHA (class III-IV) or any type of angina&#xD;
             pectoris and/or a diagnosis of myocardial infarction during the previous 6 months&#xD;
             and/or poorly controlled hypertension will be excluded, QTc &gt;450 ms at baseline,&#xD;
             additional risk factors for Torsade de Pointes (heart failure and hypokalemia (≥G1,&#xD;
             i.e. P-K &lt;LLN-2.5 mM) or family history of long QT-syndrome), cardiac arrhythmias&#xD;
             requiring anti-arrhythmics (excluding beta-blockers or digoxin for chronic atrial&#xD;
             fibrillation);&#xD;
&#xD;
          -  patients having received more than one previous systemic chemotherapy for advanced or&#xD;
             metastatic disease;&#xD;
&#xD;
          -  patients who have received any other investigational or anti-cancer therapy 14 days&#xD;
             before the inclusion;&#xD;
&#xD;
          -  other malignancies, except adequately treated basal carcinoma of the skin or in-situ&#xD;
             cervix carcinoma or incidental prostate cancer (T1a, Gleason score ≤6, PSA &lt;0.5&#xD;
             ng/ml), or any other tumour with a disease free survival of ≥5 years;&#xD;
&#xD;
          -  pregnant or lactating women;&#xD;
&#xD;
          -  men or women of childbearing potential not employing adequate contraception;&#xD;
&#xD;
          -  any psychological, familial, sociological, or geographical condition which does not&#xD;
             permit protocol compliance and medical follow-up.&#xD;
&#xD;
          -  poorly controlled hypertension. At baseline, blood pressure &gt;150/90 is defined as&#xD;
             poorly controlled.&#xD;
&#xD;
          -  renal dysfunction: creatinine clearance &lt;40 ml/min measured by either iohexol&#xD;
             clearance or Cr-EDTA technique.&#xD;
&#xD;
          -  ECOG / WHO Performance Status ≥2&#xD;
&#xD;
          -  presence of hand-foot skin reaction or rash &gt;G1 at enrolment;&#xD;
&#xD;
          -  known or suspected allergy to the investigational agent or any agents given in&#xD;
             association with this trial;&#xD;
&#xD;
          -  current medical treatment with any compound that prolongs QTc&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Ullén, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Oncology, Karolinska University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>DK-8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>November 5, 2012</study_first_submitted>
  <study_first_submitted_qc>April 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2013</study_first_posted>
  <last_update_submitted>April 25, 2019</last_update_submitted>
  <last_update_submitted_qc>April 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Dr Anders Ullén</investigator_full_name>
    <investigator_title>Associate Professor/Sr Consultant Clinical Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Ureteral Neoplasms</mesh_term>
    <mesh_term>Pelvic Neoplasms</mesh_term>
    <mesh_term>Urethral Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

